Sonnet biotherapeutics announces results of biodistribution studies demonstrating solid tumor targeting using the fhab technology

Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mil12-fhab, the mouse version of son‑1010, compared with mil-12 alone accumulation was observed in tumors compared to normal mice, and was expectedly transient in liver and kidney the model shows that the fhab technology provides tumor targeting and retention, as well as extended half-life, that importantly complements results from the human clinical studies princeton, nj / accesswire / september 20, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the fhab technology. sonnet performed two independent in vivo proof-of-concept (poc) studies to show the biodistribution of interleukin-fhab molecules to the tumor microenvironment (tme), using labs with expertise in radiolabeling biologics and in vivo biodistribution analysis.
SONN Ratings Summary
SONN Quant Ranking